This study therefore identifies IAPP oligomers as an important target for drug discovery for diabetes type II, and indicates that the design of inhibitors of secondary nucleation could be developed as a treatment to preserve or restore the function of β-cells in this disease. This evidence concerns the gene IAPP and type 2 diabetes mellitus.